Skip to main content
. 2020 Jan 29;12(2):318. doi: 10.3390/cancers12020318

Figure 3.

Figure 3

BCR-ABL-dependent and -independent imatinib resistances. BCR-ABL-dependent (purple) and -independent (blue) resistances can be explained by BCR-ABL duplication and mutation mechanisms, co-medication, interindividual variety, decreased import proteins, increased export proteins, binding of imatinib to plasma proteins, and the presence of imatinib-insensitive leukemic stem cells (LSCs). CYP3A4: cytochrome 3A4.